ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,317.59
-0.26%
Dow Jones
39,069.59
0.01%
Gold vs US Dollar
2,334.20
0.00%
Brent Oil
81.965
0.00%
Bitcoin
68,935.80
0.59%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Acer Therapeutics Inc (ACER)

  7. Acer Therapeutics Inc (ACER) News

Acer Therapeutics (ACER)

Acer Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ACER
DateTimeSourceHeadlineSymbolCompany
08/11/202321:13Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
08/11/202321:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
02/11/202312:51Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
02/11/202312:50Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
02/11/202312:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
02/11/202312:30GlobeNewswire Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related ProposalsNASDAQ:ACERAcer Therapeutics Inc
30/10/202311:24Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACERAcer Therapeutics Inc
10/10/202322:17Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:ACERAcer Therapeutics Inc
31/08/202314:29Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:ACERAcer Therapeutics Inc
31/08/202314:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
31/08/202312:30GlobeNewswire Inc.Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial ProductNASDAQ:ACERAcer Therapeutics Inc
30/08/202321:05GlobeNewswire Inc.Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical EuropeNASDAQ:ACERAcer Therapeutics Inc
14/08/202321:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACERAcer Therapeutics Inc
14/08/202321:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACERAcer Therapeutics Inc
14/08/202321:05GlobeNewswire Inc.Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
26/06/202314:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
26/06/202313:30GlobeNewswire Inc.Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and FounderNASDAQ:ACERAcer Therapeutics Inc
07/06/202321:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
22/05/202321:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
15/05/202322:29Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACERAcer Therapeutics Inc
15/05/202322:22Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
15/05/202322:10GlobeNewswire Inc.Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
04/05/202311:00Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
01/05/202314:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACERAcer Therapeutics Inc
01/05/202313:30GlobeNewswire Inc.Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of ScheduleNASDAQ:ACERAcer Therapeutics Inc
27/04/202311:25Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)NASDAQ:ACERAcer Therapeutics Inc
14/04/202321:29Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ACERAcer Therapeutics Inc
27/03/202321:18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ACERAcer Therapeutics Inc
27/03/202321:13Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACERAcer Therapeutics Inc
27/03/202321:01GlobeNewswire Inc.Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:ACERAcer Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ACER

Your Recent History

LSE
NG.
National Grid
LSE
POS
Plexus
LSE
ENET
Ethernity Networks
LSE
SRSP
Sirius Petroleum
LSE
SCLP
Scancell
LSE
VAST
Vast Resources
LSE
AVCT
Avacta
LSE
ZED
Zenova
LSE
LLOY
Lloyds Banking
LSE
CHLL
Chill Brands
LSE
HUM
Hummingbird Resources
LSE
AGL
Angle
LSE
NFDS
Northern Foods
LSE
SOS
Sosandar
LSE
TERN
Tern
LSE
KRS
Keras Resources
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved